Maxwell Chen

Mr. Maxwell Chen


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in American Journal of Hospice and Palliative Medicine®
Verified
Journal Article
Closed access
MCMaxwell Chen
Maxwell Chen
JTJoan M. Teno
Joan M. Teno
Background: Prior research has examined the impact of limited English proficiency (LEP) in the hospital setting at the end of life in select regions of the United States. Objective: Examine whether LEP is associated with bereaved family ratings of quality of care in a national survey. Design: Secondary data analysis of the National Health and Aging Trends Study (NHATS). Setting/Participants: National sample of bereaved respondents. Measurement: Last month of life survey about quality of care with decedents. Decedents classified as LEP based on need for translator, proxy use due to limited ability to speak English, and/or interview rating of understanding English. Multivariate regression model examined the overall association and interaction of LEP and Hispanic heritage after adjustment for socio-demographic, diagnoses, bereaved respondent relationship with decedent, and functional decline. Results: Of 17.1 million deaths, 5.4% occurred in Hispanic decedents, compared to 3.0% among non-Hispanics ( P ≤ .001). The strongest disparity was a 12.9-point lower adjusted quality-of-care rating for Hispanic decedents with LEP (65.6, 95% CI 55.3-76.1) compared with non-Hispanic decedents without LEP (78.5, 95% CI 77.5-79.6). These ratings were also lower than those of non-Hispanic decedents with LEP (84.1, 95% CI 74.0-94.4) as well as Hispanic decedents without LEP. Significance was determined by non-overlapping CIs. Respondents of Hispanic decedents with LEP reported trends of higher unmet needs for dyspnea palliation and receipt of goal concordant care. Conclusion: LEP is prevalent in Hispanic decedents, with those with LEP reporting lower ratings of the quality of care compared to non-Hispanics without LEP.

3 November 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
MCMaxwell Chen
Maxwell Chen
JTJay Trivedi
Jay Trivedi
Organ-on-chip (OoC) technology has emerged as a powerful class of microphysiological systems capable of recapitulating human tissue architecture, biochemical gradients, and dynamic cellular interactions with high fidelity. While OoC platforms have advanced rapidly in organs such as liver, heart, and lung, their application to the musculoskeletal system remains comparatively underdeveloped despite the central role of biomechanics in tissue function and disease. Musculoskeletal tissues, including skeletal muscle, bone, cartilage, and tendon, present unique challenges due to their hierarchical structure, anisotropic mechanical properties, and tightly coupled immune, vascular, and stromal interactions that govern repair and degeneration. In this review, we critically evaluate recent advances in musculoskeletal OoC platforms, including muscle, bone, cartilage, and tendon-on-chip systems, with emphasis on structural design, biomaterial composition, and integration of mechanical cues. We highlight how these systems enable precise control of microenvironmental conditions and support human-relevant disease modeling and drug testing. However, we identify key limitations that constrain their translational potential, including inadequate representation of physiologically relevant mechanical loading, incomplete vascular and immune integration, lack of standardization, and limited modeling of inter-tissue interfaces. Importantly, we propose a unifying framework for next-generation musculoskeletal OoC systems centered on three principles: mechanobiological fidelity, multicellular integration, and interface-level modeling of the muscle–tendon–bone axis. We further discuss emerging strategies, including advanced biomaterials, 3D bioprinting, multi-tissue integration, and artificial-intelligence-driven analysis that can address current limitations and enable scalable, predictive platforms. By bridging reductionist in vitro systems and complex in vivo physiology, musculoskeletal OoC technologies have the potential to transform mechanobiology research, accelerate drug discovery, and enable precision regenerative therapies. Realizing this potential will require coordinated advances in engineering, biology, and standardization to establish OoC platforms as robust, clinically relevant tools for musculoskeletal medicine.